Cardiac sarcoidosis: from early recognition to management

Cardiac sarcoidosis is a potentially fatal inflammatory disorder with the tendency to mostly affect the myocardial tissues. It is commonly associated with extra-cardiac structures such as the lungs and the thoracic lymph nodes; however, when it manifests as an isolated disease, it can be insidious. The clinical presentation is variable depending on the location and extent of the cardiac tissues involved, including asymptomatic cases, conduction abnormalities, arrhythmia, heart failure and sudden cardiac death (SCD). It is an enigmatic disease to diagnose owing to the variable clinical presentation; as a result, most centres are adopting a multidisciplinary approach to diagnosis, risk stratification and management. The mainstay of treatment in CS is immunosuppression, guideline-directed medical therapy for patients with heart failure in addition to device therapy for individuals at high risk of SCD, and heart transplantation for patients with advanced heart failure. We synthesise the existing evidence in the diagnosis and management of cardiac sarcoidosis in our review.

Authors

Institutions

Publication Details

Journal
Current Opinion in Immunology
Published
2026-07-27
DOI
https://doi.org/10.1016/j.coi.2026.102831
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiac sarcoidosis: from early recognition to management

Vasileios Kouranos, Wilfred Umeojiako, Rakesh Sharma
Current Opinion in Immunology
Sarcoidosis and Beryllium Toxicity Research
article

Cardiac sarcoidosis: from early recognition to management

Vasileios Kouranos, Wilfred Umeojiako, Rakesh Sharma
article en

Abstract

Cardiac sarcoidosis is a potentially fatal inflammatory disorder with the tendency to mostly affect the myocardial tissues. It is commonly associated with extra-cardiac structures such as the lungs and the thoracic lymph nodes; however, when it manifests as an isolated disease, it can be insidious. The clinical presentation is variable depending on the location and extent of the cardiac tissues involved, including asymptomatic cases, conduction abnormalities, arrhythmia, heart failure and sudden cardiac death (SCD). It is an enigmatic disease to diagnose owing to the variable clinical presentation; as a result, most centres are adopting a multidisciplinary approach to diagnosis, risk stratification and management. The mainstay of treatment in CS is immunosuppression, guideline-directed medical therapy for patients with heart failure in addition to device therapy for individuals at high risk of SCD, and heart transplantation for patients with advanced heart failure. We synthesise the existing evidence in the diagnosis and management of cardiac sarcoidosis in our review.

Current Opinion in ImmunologyVol. 102
Guy's and St Thomas' NHS Foundation Trust (GB), Royal Brompton & Harefield NHS Foundation Trust (GB), Harefield Hospital (GB)
Openalex Percentile: Top 10%
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cardiac sarcoidosis: from early recognition to management — Vasileios Kouranos, Wilfred Umeojiako, et al. · Current Opinion in Immunology (2026) | TGRS Research Map | TGRS